Citicoline was found to enhance retinal function and neural conduction along post-retinal visual pathways, such that responses of the visual cortex to stimuli were significantly improved compared to placebo (87)
Retatrutide has not been approved by the MHRA, EMA, or FDA
Patients should be educated about red flag symptoms requiring urgent medical review, including: Severe, persistent abdominal pain (possible pancreatitis) Right upper quadrant pain, fever, or jaundice (possible gallbladder disease) Signs of dehydration (dizziness, reduced urine output, dry mouth) Symptoms of hypersensitivity (rash, swelling, breathing difficulties) Unexplained neck swelling or hoarseness (thyroid concerns) Severe hypoglycaemia (confusion, loss of consciousness) New or worsening visual symptoms Regular follow-up with the prescribing clinician, typically a GP or specialist diabetes team, ensures that any concerns are addressed promptly and that treatment remains appropriate for the individual patient's needs
The dose schedule guide covers missed-dose protocols in detail
